University of Helsinki

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can influence drug response.

Investigators pooled older and new data from the Prospective Lynch Syndrome Database, tracking outcomes for different mutations across age and gender groups.

The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.